Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00807937 · ClinicalTrials.gov registry record · Phase 2
Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 369
- Enrollment target
NCT00807937: Completed Phase 2 study, sponsored by AstraZeneca.
NCT00807937 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 369 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (177% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00807937, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 369 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine whether AstraZeneca's drug AZD7325 is safe and effective in the treatment of generalized anxiety disorder.
Primary Outcome
HAM-A total score 0-56 units, 14 questions scored on scale of 0-4 (0= Not present, 4=Very severe) . Higher HAM-A scores indicate higher levels of anxiety Change : score at week 4 minus score at randomization
Interventions
- DRUG Placebo
- DRUG Lorazepam
- DRUG AZD7325
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 369 participants |
| Start Date | 2008-12 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
What the finished NCT00807937 record still lists
NCT00807937 is an interventional study that assigns participants to a tested intervention. The registered 369 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (177% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00807937 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00807937 about?
NCT00807937 is a clinical study titled "Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325". The purpose of this research study is to determine whether AstraZeneca's drug AZD7325 is safe and effective in the treatment of generalized anxiety disorder.
What is the current status of trial NCT00807937?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 369 participants. The study started on 2008-12. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00807937?
The interventions under investigation include: Placebo (DRUG), Lorazepam (DRUG), AZD7325 (DRUG).
Who is sponsoring clinical trial NCT00807937?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00807937's enrollment target sits among peer trials
369 121st of 2000 higher than 1,880 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06114836 · 369 participants · NA
GERD Infant Feeding Therapeutics Trial (GIFT Trial)
- NCT06585410 · 369 participants · Phase 3
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
- NCT07256717 · 369 participants · NA
BPIT 5-Week Multi-Site Study: Movement Efficiency, Mobility & Neuromuscular Adaptation
- NCT02332668 · 370 participants · Phase 1
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia